Visible light catalytic cross-linked virus-like ruthenium oxide nanoparticles for efficient transmembrane treatment of keratoconus
Through visible light catalyzed virus-like ruthenium oxide nanoparticles, the single electron transfer reaction of ruthenium oxide under ammonium persulfate is used to achieve covalent cross-linking of corneal collagen fibers and glycoproteins, solving the problem of ultraviolet light irradiation in the prior art The problems of safety risks and low corneal epithelial permeability have achieved non-invasive and efficient keratoconus treatment, which has improved patient compliance and overall cross-linking intensity of the cornea.
Patent Information
- Application Number
- CN202411040380.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-07-31
AI Technical Summary
In the prior art, when treating keratoconus, ultraviolet light irradiation brings safety risks and corneal damage. In addition, traditional drugs have low permeability to the corneal epithelium, making it difficult to achieve double crosslinking, which fails to effectively improve the overall crosslinking intensity of the cornea.
Virus-like ruthenium oxide nanoparticles catalyzed by visible light, and the single electron transfer reaction of ruthenium oxide under ammonium persulfate and visible light can be achieved by mimicking the nanoscale and surface characteristics of viruses in nature. reduces damage to the cornea.
The corneal can be efficiently cross-linked without ultraviolet light, reducing postoperative complications, improving patient compliance and quality of life, achieving closer corneal cross-linking, and enhancing the biomechanical properties of the corneal.
Smart Images

Figure CN118986895A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a visible light-catalyzed cross-linked virus-like ruthenium oxide nanoparticle for efficient transmembrane treatment of keratoconus. Background Art
[0002] Keratoconus is a progressive corneal disease that causes non-inflammatory progressive thinning of the central or paracentral part of the cornea and a cone-shaped protrusion forward, causing irregular astigmatism, myopia, and even blindness. Due to the irreversibility of keratoconus, the goal of treatment is to prevent the progression of the disease and improve vision. In terms of clinical treatment methods, corneal collagen cross-linking is currently a relatively mature method for treating keratoconus. It has a 20-year clinical history and can effectively prevent or slow the development of keratoconus. The cross-linking surgery uses the photosensitizer riboflavin to scrape off part of the corneal epithelium or with the assistance of various penetration enhancers (MI2007A002162, CN102470120A, CN102164592B and CN115177729B, etc.), cross-corneal epithelial cells into the corneal stroma, and cross-links through ultraviolet light irradiation to enhance the strength of the corneal collagen fiber layered structure, balance the internal tension of the cornea, and prevent the cornea from expanding continuously. However, ultraviolet light exposure can bring certain safety risks (such as irreversible damage to the corneal epithelium and corneal edema, permanent corneal opacity, corneal endothelial failure, etc.) and patient discomfort. In addition, the use of penetration enhancers increases the risk of corneal cell damage. Therefore, a cross-linking agent that can efficiently cross the corneal epithelial cells into the corneal stroma without a penetration enhancer and can cross-link without ultraviolet light exposure can not only reduce damage to the cornea and avoid a variety of possible postoperative complications, improve the safety of treatment, but also enhance the patient's treatment experience.
[0003] Compared with the traditional riboflavin as a photosensitizer, the photocatalytic activity of ruthenium-based derivatives allows for effective cross-linking reactions under lower energy light sources, promoting single electron transfer reactions under the catalysis of visible light, thereby effectively catalyzing the oxidation of tyrosine residues and achieving cross-linking of proteins and collagen fibers. Viruses in nature have highly evolved transmembrane transport mechanisms due to their unique nanoscale and biological characteristics, and can effectively interact with host cell membranes and promote transmembrane transport of substances. Therefore, the present invention provides a visible light-catalyzed cross-linked virus-like ruthenium oxide nanoparticle for efficient cross-coronal epithelium and treatment of keratoconus under visible light catalysis, which is expected to improve the compliance and quality of life of patients with keratoconus.
[0004] In order to further explain the characteristics of the present invention, the applicant further conducted relevant searches and the following is a preliminary explanation:
[0005] Prior art WO2024054165A1 discloses a method and pharmaceutical composition for treating eye diseases by visible light-induced corneal cross-linking using a ruthenium compound, which comprises a therapeutically effective amount of a ruthenium compound and sodium persulfate; a pharmaceutically acceptable carrier;
[0006] WO2017095240A1 mentions that ruthenium and SPS (sodium persulfate) compounds are used together as photoinitiators for photopolymerization processes. The wavelength range used is between 400-700nm, more preferably 400-450nm. It is said that the method using visible light and a ruthenium-SPS mixture has less phototoxicity to cells and can be used for tissue engineering. However, this prior art is mainly used to make hydrogels.
[0007] Through the above explanation of the prior art, those skilled in the art can know that the relevant drugs currently used to treat keratoconus have the following characteristics:
[0008] 1. Most existing technologies are based on riboflavin, which generates singlet oxygen or free radicals by ultraviolet light excitation, and establishes covalent cross-linking bonds between functional groups of amino acid residues on collagen fibers;
[0009] 2. Methods and pharmaceutical compositions for visible light-induced corneal cross-linking using ruthenium compounds, as represented by WO2024054165A1.
[0010] However, these two technologies have the following defects:
[0011] (1) Riboflavin has a very low permeability to the corneal epithelial matrix. During the treatment, the eyes need to be exposed to ultraviolet light for a long time (about 30 minutes in total), which can easily cause irreversible damage to the corneal epithelium and increase the risk of postoperative complications such as corneal edema, permanent corneal opacity, and corneal endothelial failure.
[0012] (2) Although WO2024054165A1 is based on ruthenium compounds and sodium persulfate, the synergistic effect of the two is still small, and the technology does not solve the problem of low permeability to the corneal epithelial mechanism. When used, the corneal epithelium needs to be scraped off, which is prone to cause various postoperative complications such as infection and corneal melting;
[0013] (3) Most existing technologies currently only cross-link corneal collagen and fail to achieve a tighter corneal cross-linking treatment through a double cross-linking mechanism (cross-linking glycoproteins in the corneal stroma and corneal collagen fibers);
[0014] (4) Currently, most existing technologies fail to pay attention to the technical research and development route for preparing virus-like nanoparticles, nor to the use of nanoscale and biological topological structures to promote trans-epithelial efficiency. In addition, they also fail to pay attention to the use of the cations on the surface of virus-like cationic ruthenium-based nanoparticles and the negative charge on the surface of corneal epithelial cells to achieve efficient trans-epithelial penetration into the corneal stroma through adsorption-mediated effects. Summary of the invention
[0015] The present invention provides a visible light-catalyzed cross-linked virus-like ruthenium oxide nanoparticle, which can efficiently cross the corneal epithelium and cross-link corneal collagen fibers without ultraviolet light. It is easy to use and can treat keratoconus painlessly and non-invasively, which is of great significance for improving the compliance and quality of life of patients with keratoconus.
[0016] The invention provides a visible light catalytic cross-linked virus-like ruthenium oxide nanoparticles, which are mainly prepared from the following components in mass percentage: 3% to 5% hexadecyltrimethylammonium bromide, 4% to 8% sodium hydroxide, 15% to 25% tetraethyl orthosilicate, 70% to 90% cyclohexane, 0.5% to 1% ruthenium chloride, 0.5% to 15% amphetamine, and the remaining components are pharmaceutically acceptable components or excipients. Those skilled in the art can understand that the mass fraction is used here.
[0017] The visible light-catalyzed cross-linked virus-like ruthenium oxide nanoparticles provided by the present invention are mainly prepared by the following steps:
[0018] Step 1: Preparation of virus-like silica nanoparticles
[0019] The method is mainly prepared from the following components: deionized water, hexadecyltrimethylammonium bromide, sodium hydroxide, tetraethyl orthosilicate and cyclohexane. The hexadecyltrimethylammonium bromide and the sodium hydroxide are mixed and dissolved in 50-80 mL of deionized water, and after being fully stirred at a speed of 200-500 rpm at 40° C.-80° C., the mixture is dripped into a mixed solution prepared by mixing the tetraethyl orthosilicate and the cyclohexane, and stirred at a high speed of not less than 1000 rpm for 60-90 hours, and the virus-like silica nanoparticles are collected by centrifugation.
[0020] Step 2: Preparation of virus-like ruthenium oxide nanoparticles
[0021] The method is mainly prepared from the following components: the virus-like silica nanoparticles, ruthenium chloride, amphetamine and deionized water. The virus-like silica nanoparticles and the ruthenium chloride are mixed and added into 50-80 mL of deionized water, and after being fully stirred at a speed of not less than 1000 rpm, amphetamine is added, stirring is continued for 3-5 hours, and the virus-like silica-ruthenium nanoparticles are obtained by centrifugation.
[0022] Step 3: Preparation of virus-like ruthenium oxide nanoparticles
[0023] The method is mainly prepared from the following components: the virus-like silicon dioxide-ruthenium nanoparticles, sodium hydroxide and deionized water. The sodium hydroxide is dissolved in the deionized water to prepare a sodium hydroxide solution with a pH of 8-10, the virus-like silicon dioxide-ruthenium nanoparticles are immersed in a sufficient amount of sodium hydroxide solution for an etching reaction for 30-60 minutes, and the virus-like ruthenium oxide nanoparticles with silicon dioxide removed are collected by centrifugation.
[0024] The present invention provides a method for using a visible light-catalyzed cross-linked virus-like ruthenium oxide nanoparticle, which also includes 1%-2% ammonium persulfate (those skilled in the art will understand that this is the mass fraction or concentration, preferably the mass fraction). The virus-like ruthenium oxide nanoparticles are first dispersed in an appropriate amount of deionized water, ultrasonically dispersed in an ultrasonic cleaning machine for 300-600 seconds, and then ammonium persulfate is added. After being fully stirred until the ammonium persulfate is completely dissolved, an ophthalmic solution is prepared; the ophthalmic solution is dripped dropwise on the surface of the keratoconus eye, and after infiltration for about 30-50 minutes, it is irradiated with visible light for 5-10 minutes, and repeated 2-5 times.
[0025] Specifically, the visible light band ranges from 450 to 680 nm, and the intensity is 1 to 3 W / cm2.
[0026] The present invention also relates to the use of visible light-catalyzed cross-linked virus-like cationic ruthenium-based nanoparticles in the preparation of ophthalmic preparations;
[0027] Furthermore, the ophthalmic preparation is used to prevent or treat corneal biomechanical property degenerative diseases;
[0028] Furthermore, the ophthalmic solution used only contains visible light-catalyzed cross-linked virus-shaped cationic ruthenium-based nanoparticles and pharmaceutically acceptable excipients.
[0029] Further, the ophthalmic preparation is a solution preparation, and the concentration of the visible light-catalytically cross-linked virus-shaped cationic ruthenium-based nanoparticles is 0.8-1.5 mg / mL;
[0030] Furthermore, the pharmaceutically acceptable excipient is one or more selected from an osmotic pressure regulator, a preservative, a solubilizing agent, and a pH regulator; the osmotic pressure regulator is selected from sodium chloride and glucose; the preservative is selected from sodium thimerosal, benzalkonium chloride, benzalkonium bromide, and chlorobutanol; the solubilizing agent is selected from Tween-80 and Tween-20; the pH regulator is selected from sodium hydroxide and hydrochloric acid;
[0031] Further, the concentration of the visible light catalytic cross-linked virus-shaped cationic ruthenium-based nanoparticles is 0.5-1.0 mg / mL;
[0032] Furthermore, the ophthalmic preparation is 0.3 ml / tube and is composed of the following components in mass fractions: 1%-2% ammonium sulfate, 30%-60% of the visible light catalytic cross-linked virus-like cationic ruthenium-based nanoparticles, and the remaining components are pharmaceutically acceptable components or excipients.
[0033] Compared with the prior art, the present invention provides a method having the following beneficial effects:
[0034] 1. The invention discloses a visible light-catalyzed cross-linked virus-like ruthenium oxide nanoparticle, which can efficiently cross the corneal epithelial cell membrane and enter the corneal stroma without scraping the patient's corneal epithelium or using various penetration enhancers, thereby reducing eye complications and improving patient compliance.
[0035] 2. The present invention discloses a visible light-catalyzed cross-linked virus-like ruthenium oxide nanoparticle, which utilizes ruthenium oxide to produce a single electron transfer reaction under the catalysis of ammonium persulfate and visible light, and then oxidizes and cross-links the tyrosine groups in the corneal collagen fibers through covalent bonds, thereby avoiding damage to the eyes caused by ultraviolet light catalysis. The nanoparticles are easy to use, non-invasive, and reduce the discomfort of patients during treatment, thereby improving patient compliance. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 is a transmission electron microscope image of the virus-like ruthenium oxide nanoparticles of the present invention;
[0037] Figure 2 X-ray photoelectron spectrum of the virus-like ruthenium oxide nanoparticles of the present invention for treating keratoconus;
[0038] Figure 3 Schematic diagram of visible light-catalyzed cross-linking of virus-like ruthenium oxide nanoparticles of the present invention;
[0039] Figure 4 This is a confocal microscopy image of the virus-like ruthenium oxide nanoparticles of the present invention crossing the corneal epithelium;
[0040] Figure 5 This is a photo of the in vitro rabbit cornea treated with the virus-like ruthenium oxide nanoparticles of the present invention. DETAILED DESCRIPTION
[0041] The technical scheme of the present invention will be further described in detail below in conjunction with the accompanying drawings and specific implementation cases. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.
[0042] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention.
[0043] Example 1 provides a specific preparation example of the virus-like ruthenium oxide nanoparticles:
[0044] Preparation of virus-like silica nanoparticles
[0045] Take 0.75g of hexadecyltrimethylammonium bromide and 1mg of sodium hydroxide respectively, mix and dissolve in 60mL of deionized water, stir thoroughly at 350 rpm at 50°C, then add dropwise into a mixed solution prepared by mixing 4mL of tetraethyl orthosilicate and 16mL of cyclohexane, stir at 1000 rpm for 72 hours, and collect by centrifugation to obtain virus-like silica nanoparticles for later use.
[0046] Preparation of virus-like ruthenium oxide nanoparticles
[0047] Take 100 mg of the virus-like silica nanoparticles and 100 mg of ruthenium chloride prepared above, mix and disperse in 50 mL of deionized water, stir thoroughly at 1500 rpm, add 120 mg of amphetamine, continue stirring at 1500 rpm for 3 hours, and collect by centrifugation to obtain virus-like silica-ruthenium nanoparticles for later use.
[0048] Preparation of virus-like ruthenium oxide nanoparticles
[0049] Take an appropriate amount of the sodium hydroxide and dissolve it in the deionized water to prepare a sodium hydroxide solution with a pH of 8, immerse the virus-like silica-ruthenium nanoparticles prepared above in 10 mL of the sodium hydroxide solution, etch for 30 minutes, and then collect by centrifugation to obtain the virus-like ruthenium oxide nanoparticles with the silica removed.
[0050] Example 2 provides another specific preparation example of the virus-like ruthenium oxide nanoparticles:
[0051] (1) Preparation of virus-like silica nanoparticles
[0052] Take 1 g of hexadecyltrimethylammonium bromide and 1 mL of 0.1 M sodium hydroxide solution respectively, mix and dissolve in 80 mL of deionized water, stir thoroughly at 60°C at 500 rpm, then add dropwise into a mixed solution prepared by mixing 5 mL of tetraethyl orthosilicate and 18 mL of cyclohexane, stir at 1500 rpm for 80 hours, and collect by centrifugation to obtain virus-like silica nanoparticles for later use.
[0053] (2) Preparation of virus-like ruthenium oxide nanoparticles
[0054] Take 100 mg of the virus-like silica nanoparticles and 120 mg of ruthenium chloride prepared above, mix and disperse in 60 mL of deionized water, stir thoroughly at 2000 rpm, add 140 mg of amphetamine, continue stirring at 2000 rpm for 3 hours, collect by centrifugation to obtain virus-like silica-ruthenium nanoparticles, and set aside.
[0055] (3) Preparation of virus-like ruthenium oxide nanoparticles
[0056] Take an appropriate amount of the sodium hydroxide and dissolve it in the deionized water to prepare a sodium hydroxide solution with a pH of 9, immerse the virus-like silica-ruthenium nanoparticles prepared above in 10 mL of the sodium hydroxide solution, etch for 30 minutes, and collect by centrifugation to obtain the virus-like ruthenium oxide nanoparticles with the silica removed.
[0057] Example 3 provides the specific use method and treatment conditions of the virus-like ruthenium oxide nanoparticles visible light catalytic cross-linking treatment of in vitro rabbit cornea. Weigh 1 mg of virus-like ruthenium oxide nanoparticles and disperse them in 1 mL of deionized water. Place them in an ultrasonic cleaner for ultrasonic dispersion for 360 seconds, then add 15 μg of ammonium persulfate and stir thoroughly until the ammonium persulfate is completely dissolved to prepare an ophthalmic solution. Use a dropper to draw the ophthalmic solution and drop it drop by drop on the rabbit corneal surface. After soaking for 40 minutes, irradiate with 2W / cm2 of 600nm visible light for 8 minutes, and repeat 3 times. Figure 3 As shown, the ammonium persulfate is dissolved in deionized water and reacts with the virus-like ruthenium oxide nanoparticles. The valence state of ruthenium in ruthenium oxide changes from 3+ to 4+, and the ammonium persulfate is oxidized to produce sulfacyl radicals, which further oxidize the tyrosine groups in the corneal collagen fibers to form dityrosine bonds, thereby cross-linking the corneal collagen fibers. In order to evaluate the ability of the virus-like ruthenium oxide nanoparticles to cross the ex vivo rabbit corneal epithelium, the virus-like ruthenium oxide nanoparticles used for ex vivo rabbit corneal treatment were stained and labeled with fluorescein isothiocyanate dye, and the ability of the virus-like ruthenium oxide nanoparticles to cross the rabbit corneal epithelium was observed using a confocal microscope, as shown in FIG. Figure 4 As shown, virus-like ruthenium oxide nanoparticles can efficiently cross the rabbit corneal epithelium and enter the corneal stroma; in order to evaluate the treatment of virus-like ruthenium oxide nanoparticles on isolated rabbit corneas, the isolated rabbit corneas treated with virus-like ruthenium oxide nanoparticles were immersed in 20 mL of 0.1% collagen fiber dissolving enzyme solution, as shown in FIG. Figure 5 As shown, the isolated rabbit cornea treated with virus-like ruthenium oxide nanoparticles visible light catalytic cross-linking was able to resist the degradation of collagen fiber dissolving enzymes and still retained 60% of the cornea after 12 hours.
[0058] Comparative Example 1 provides the treatment of riboflavin combined with ultraviolet light in the treatment of isolated rabbit cornea:
[0059] Take 1 mg of riboflavin molecules and dissolve them in 1 mL of deionized water to prepare a riboflavin ophthalmic solution. Incubate at room temperature for 30 minutes. Use a dropper to draw 300 μL of riboflavin ophthalmic solution each time and drop it on the rabbit cornea surface. After 30 minutes, irradiate with 365 nm ultraviolet light with an intensity of 3 W / cm2 for 10 minutes. Repeat 3 times with an interval of 10 minutes each time. Use fluorescein isothiocyanate dye to stain and mark the riboflavin molecules used for in vitro rabbit corneal treatment. Use confocal microscopy to observe the ability of riboflavin molecules to cross the rabbit corneal epithelium, such as Figure 4 As shown in the figure, virus-like ruthenium oxide nanoparticles are much more efficient than riboflavin molecules in crossing the rabbit corneal epithelium; the isolated rabbit cornea treated with riboflavin molecules combined with ultraviolet light intervention was placed in 20 mL of 0.1% collagen fiber dissolving enzyme solution, as shown in the figure. Figure 5 As shown, the in vitro rabbit cornea treated with riboflavin molecules combined with ultraviolet light intervention was completely degraded after 12 hours.
[0060] In addition, it is clear to those skilled in the art that the various components in the present invention are either mass fractions or volume fractions, and the other unmentioned components are pharmaceutically acceptable components or excipients, which will not be described in detail here.
[0061] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A visible light-catalyzed cross-linked virus-like ruthenium oxide nanoparticle, characterized in that: The composition comprises the following components in percentage by weight: 3% to 5% of hexadecyltrimethylammonium bromide, 4% to 8% of sodium hydroxide, 15% to 25% of tetraethyl orthosilicate, 70% to 90% of cyclohexane, 0.5% to 1% of ruthenium chloride, 0.5% to 15% of amphetamine, and the remaining components are pharmaceutically acceptable components or excipients.
2. A method for preparing the visible light-catalyzed cross-linked virus-like ruthenium oxide nanoparticles as claimed in claim 1, characterized in that: The method comprises three steps of preparing virus-like silica nanoparticles, preparing virus-like ruthenium oxide nanoparticles and preparing virus-like ruthenium oxide nanoparticles.
3. The method for preparing visible light-catalyzed cross-linked virus-like ruthenium oxide nanoparticles according to claim 2, characterized in that: In the step of preparing the virus-like silica nanoparticles, the raw materials used include deionized water, hexadecyltrimethylammonium bromide, sodium hydroxide, tetraethyl orthosilicate and cyclohexane. The hexadecyltrimethylammonium bromide and the sodium hydroxide are mixed and dissolved in 50-80 mL of deionized water. After being fully stirred at a speed of 200-500 rpm at 40° C.-80° C., a mixed solution prepared by mixing the tetraethyl orthosilicate and the cyclohexane is added dropwise. The mixture is stirred at a speed of not less than 1000 rpm for 60-90 hours, and the virus-like silica nanoparticles are collected by centrifugation.
4. The method for preparing virus-like ruthenium oxide nanoparticles cross-linked by visible light catalysis according to any one of claims 2 or 3, characterized in that: In the step of preparing the virus-like ruthenium oxide nanoparticles, the raw materials used include the virus-like silica nanoparticles, ruthenium chloride, amphetamine and deionized water. The virus-like silica nanoparticles and the ruthenium chloride are mixed and added into 50-80 mL of deionized water. After stirring for 20-40 minutes at a speed of not less than 1000 rpm, the amphetamine is added, stirring is continued for 3-5 hours, and the virus-like silica-ruthenium nanoparticles are collected by centrifugation.
5. The method for preparing virus-like ruthenium oxide nanoparticles cross-linked by visible light catalysis according to any one of claims 2 or 3, characterized in that: In the step of preparing the virus-like ruthenium oxide nanoparticles, the raw materials used include the virus-like silica-ruthenium nanoparticles, sodium hydroxide and deionized water; the sodium hydroxide is dissolved in the deionized water to prepare a sodium hydroxide solution with a pH of 8-10, the virus-like silica-ruthenium nanoparticles are immersed in the sodium hydroxide solution for an etching reaction for 20-30 minutes, and the virus-like ruthenium oxide nanoparticles with silica removed are obtained by centrifugation.
6. A method for using the visible light-catalyzed cross-linked virus-like ruthenium oxide nanoparticles prepared by the preparation method according to any one of claims 2 to 5, characterized in that: The method of use also includes using 1%-2% ammonium persulfate, first dispersing the virus-like ruthenium oxide nanoparticles in deionized water, ultrasonically dispersing in an ultrasonic cleaning machine for 300-600 seconds, adding ammonium persulfate, stirring until the ammonium persulfate is completely dissolved to obtain an ophthalmic solution, dropping the ophthalmic solution drop by drop on the keratoconus eye surface, soaking for 30-50 minutes, then irradiating with visible light for 5-10 minutes, and repeating 2-5 times; The visible light wavelength range is preferably 450-680nm, and the intensity is 1-3W / cm 2 ; After the ammonium persulfate is dissolved in deionized water, it reacts with the virus-like ruthenium oxide nanoparticles, and the valence state of ruthenium in the ruthenium oxide changes from 3+ to 4+, and the ammonium persulfate is oxidized to produce sulfacyl radicals, which further oxidize the tyrosine groups in the corneal collagen fibers to form dityrosine bonds, thereby cross-linking the corneal collagen fibers.
7. Use of the visible light-catalytically cross-linked virus-like ruthenium oxide nanoparticles as claimed in claim 1 in the treatment of keratoconus.
8. A method for using the visible light-catalytically cross-linked virus-like ruthenium oxide nanoparticles according to any one of claims 2 to 6 for the treatment of keratoconus.
9. Use of visible light-catalyzed cross-linked virus-like ruthenium oxide nanoparticles in the preparation of ophthalmic preparations.
10. The use according to claim 9, wherein the ophthalmic preparation is used for preventing or treating corneal biomechanical property degenerative diseases.
Citation Information
Patent Citations
Silicon dioxide nano particles with bent spikes and preparation method thereof
CN113264535A
Virus-like particle conjugates for diagnosis and treatment of tumors
US20160228568A1
A method and a pharmaceutical composition for visible light-induced corneal crosslinking with ruthenium compounds for the treatment of eye disorders
WO2024054165A1
AU2014306363A1
